Dr. Michael Martin is the head of Takeda Ventures, Inc. (TVI) and he is based in San Diego, CA. His professional background includes venture capital, pharma business development and broad R&D experiences with an integral role in the discovery and preclinical/clinical development of 17 innovative investigational drugs and 2 commercial products. Prior to TVI, Dr. Martin was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for globally sourcing and transacting technologies and early stage pipeline programs. Dr. Martin joined Takeda in January 2012 through the acquisition of Intellikine where he was Vice President of Development. Additionally, he has held executive and senior management and scientific positions with TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals, and Monsanto Corporation. Dr. Martin earned his doctorate in Medicinal Chemistry from the University of Illinois and holds a M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.